THE ANTIBODY-DRUG CONJUGATE ABT-414 DEMONSTRATES SINGLE-AGENT ANTI-CANCER ACTIVITY ACROSS A PANEL OF GBM PATIENT-DERIVED XENOGRAFTS

被引：0
|
作者：
Marin, Bianca [1 ]
Mladek, Ann [2 ]
Burgenske, Danielle [2 ]
He, Lihong [1 ]
Hu, Zeng [2 ]
Bakken, Katrina [2 ]
Carlson, Brett [2 ]
Schroeder, Mark [2 ]
Sarkaria, Jann [3 ]
机构：
[1] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA
[2] Mayo Clin, Rochester, MN USA
[3] Mayo Clin, Translat Neurooncol Lab, Rochester, MN USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
DDIS-01
引用
收藏
页码：69 / 69
页数：1
相关论文
共 37 条
  • [21] An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy
    Bakema, Jantine E.
    Stigter-van Walsum, Marijke
    Harris, Jeffrey R.
    Ganzevles, Sonja H.
    Muthuswamy, Anantharaman
    Houtkamp, Mischa
    Plantinga, Theo S.
    Bloemena, Elisabeth
    Brakenhoff, Ruud H.
    Breij, Esther C. W.
    van de Ven, Rieneke
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (02) : 187 - 198
  • [22] KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations
    Zhang, Xiaoshan
    Zhang, Ran
    Chen, Huiqin
    Wang, Li
    Ren, Chenghui
    Pataer, Apar
    Wu, Shuhong
    Meng, Qing H.
    Ha, Min Jin
    Morris, Jeffrey
    Xi, Yuanxin
    Wang, Jing
    Zhang, Jianhua
    Gibbons, Don L.
    Heymach, John, V
    Meric-Bernstam, Funda
    Minna, John
    Swisher, Stephen G.
    Roth, Jack A.
    Fang, Bingliang
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (12): : 4464 - +
  • [23] IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum resistant epithelial ovarian cancer (EOC) patients (pts).
    Moore, Kathleen N.
    Martin, Lainie P.
    Matulonis, Ursula A.
    Konner, Jason A.
    Seward, Shelly Marie
    Bauer, Todd Michael
    O'Malley, David M.
    Perez, Raymond P.
    Jeong, Woondong
    Zhou, Yinghui
    Kirby, Maurice William
    Mohanavelu, Satishkumar
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models.
    Cho, Song
    Zammarchi, Francesca
    Monks, Noel R.
    Vashisht, Kapil
    Tammali, Ravinder
    Schifferli, Kevin
    Strout, Patrick
    King, Wanda
    Dacosta, Karma
    Fleming, Ryan
    Williams, David G.
    Havenith, Karin
    Hinrichs, Mary Jane Masson
    Chivers, Simon
    Dimasi, Nazzareno
    Howard, Phil W.
    Hartley, John A.
    Coats, Steve
    Herbst, Ronald
    van Berkel, Patrick H.
    Tice, David A.
    CANCER RESEARCH, 2018, 78 (16) : 25 - 25
  • [25] Potent anti-cancer activity of DS6-DM1, an antibody-drug conjugate targeting a Mucl glycotope on ovarian, breast, and pancreatic carcinomas.
    Chun, P
    Xie, HS
    Dionne, CA
    Medina, LA
    Lutz, RJ
    Seier, A
    Kellogg, AE
    Payne, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6186S - 6186S
  • [26] Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer
    Li, Shunqiang
    Maureen, Highkin
    Primeau, Tina M.
    Pratt, Stephanie L.
    Diala, Irmina
    Cutler, Richard E.
    Mann, Grace
    Lalani, Alshad S.
    Ma, Cynthia X.
    Bose, Ron
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)
    Spigel, David
    Pietanza, M. Catherine
    Bauer, Todd
    Ready, Neal
    Morgensztern, Daniel
    Glisson, Bonnie S.
    Byers, Lauren Averett
    Johnson, Melissa
    Burris, Howard
    Robert, Francisco
    Han, Tae
    Bheddah, Sheila
    Theiss, Noah
    Watson, Sky
    Mathur, Deepan
    Vennapusa, Bharathi
    Strickland, Donald
    Zayed, Hany
    Dylla, Scott
    Peng, Stanford
    Govindan, Ramaswamy
    Rudin, Charles
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S260 - S261
  • [28] MAT2A inhibitor, IDE397, displays broad anti-tumor activity across a panel of MTAP-deleted patient-derived xenografts.
    Fischer, Marcus M.
    Bhola, Neil
    Faulhaber, John
    Freyman, Yevgeniy
    Yao, Bing
    Mounir, Zineb
    Lackner, Mark R.
    Neilan, Claire
    CANCER RESEARCH, 2021, 81 (13)
  • [29] Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia
    Lock, Richard B.
    Evans, Kathryn
    Randall, Joanna
    Erickson, Stephen W.
    Earley, Eric J.
    Neuhauser, Steven
    Stearns, Tim
    Philip, Vivek
    Teicher, Beverly A.
    Watkins, Krystal
    Sloss, Callum M.
    Zweidler-McKay, Patrick A.
    Smith, Malcolm A.
    BLOOD, 2022, 140 : 8983 - 8984
  • [30] AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts
    Rudra-Ganguly, Nandini
    Lowe, Christine
    Virata, Cyrus
    Leavitt, Monica
    Jin, Liqing
    Mendelsohn, Brian
    Snyder, Josh
    Avina, Hector
    Zhang, Chunying
    Russell, Deanna L.
    Mattie, Michael
    Yang, Peng
    Randhawa, Baljinder
    Liu, Gao
    Malik, Faisal
    Vest, Misty
    Abad, Joseph D.
    Kemball, Christopher C.
    Hubert, Rene
    Karki, Sher
    Anand, Banmeet
    An, Zili
    Grant, Jeanette
    Dick, John E.
    Donate, Fernando
    Morrison, Kendall
    Challita-Eid, Pia
    Joseph, Ingrid B.
    Pereira, Daniel S.
    Stover, David R.
    BLOOD, 2015, 126 (23)
1234